Health Care Supplies

Tellgen

Tellgen released FY2025 Annual Earnings on April 24 After-Market (BJT), actual revenue CNY 363.83 M (forecast CNY 441 M), actual EPS CNY 0.022 (forecast CNY 1.14)

Tellgen released FY2025 Q4 earnings on April 24 After-Market (BJT), actual revenue CNY 106.22 M, actual EPS CNY -0.0131

Tellgen released FY2026 Q1 earnings on April 24 After-Market (BJT), actual revenue CNY 82.61 M, actual EPS CNY -0.0348

Tellgen to Release FY2026 Q1 Earnings on April 25 After-Market (BJT)

Tellgen to Release FY2025 Earnings on April 25 After-Market (BJT), Forecast Revenue CNY 441 M, EPS CNY 1.14

Tellgen released FY2025 9 Months Earnings on October 22 After-Market (BJT), actual revenue CNY 257.61 M, actual EPS CNY 0.0356

Tellgen released FY2025 Q3 earnings on October 22 After-Market (BJT), actual revenue CNY 98.55 M, actual EPS CNY 0.0186

Tellgen to Release FY2025 Q3 Earnings on October 23 After-Market (BJT)

Tellgen released FY2025 Q2 earnings on August 26 Pre-Market (BJT), actual revenue CNY 84.17 M, actual EPS CNY 0.0141

Tellgen released FY2025 Semi-Annual earnings on August 26 Pre-Market (BJT), actual revenue CNY 159.06 M, actual EPS CNY 0.017

Tellgen to Release FY2025 Semi-Annual Earnings on August 27, 2025 (BJT)

Jiangxi Tounjink Life Sciences Obtained Two Medical Device Registrations

Taoke Life's Multiple Medical Device Registrations Accepted by Shanghai FDA

Shanghai Rongzhen Plans to Reduce Shares in Tousheng Life

Tongjing Life Revenue Down 19.53% in Q1 2025

Tellgen released FY2025 Q1 earnings on April 27 After-Market BJT, actual revenue CNY 74.89 M, actual EPS CNY 0.0029

Tellgen FY2025 Q1 Earnings Release on April 28 After-Market BJT

Tellgen released FY2024 Q4 earnings on April 18 After-Market BJT, actual revenue CNY 115.86 M, actual EPS CNY 0.0627

Tellgen released FY2024 Annual Earnings on April 18 After-Market (BJT), actual revenue CNY 436.78 M (forecast CNY 429 M), actual EPS CNY 0.213 (forecast CNY 0.84)

Tellgen to Release FY2024 Annual Earnings on April 19 After-Market (BJT), Forecast Revenue CNY 711.05 M, EPS CNY 0.84

Ordinary dividend (cash)

Ex Date: 2026.05.26, Cash dividend 0.1 CNY

300642

Tellgen released its Q3 2025 report, with operating revenue for the first three quarters amounting to 258 million yuan, a year-on-year decrease of 19.73%. The net profit attributable to the parent company was 5.7749 million yuan, a year-on-year decline of 76.33%; the net profit after deducting non-recurring gains and losses was 1.3732 million yuan, a year-on-year decrease of 90.45%. The basic earnings per share were 0.0356 yuan

Zhitong

Tellgen released its performance for the first three quarters, with a net profit attributable to the parent company of 5.7749 million yuan, a decrease of 76.33%

Tellgen announced that the company will repurchase 737,000 shares through centralized bidding from August 28, 2025, to September 30, 2025, accounting for 0.45% of the company's current total share capital. The maximum repurchase price is RMB 29.34 per share, the minimum price is RMB 23.89 per share, and the total amount is RMB 20.0269 million. All repurchased shares will be used for the employee stock ownership plan or equity incentive plan

Tellgen: Completed the repurchase of 737,000 shares

Tellgen announced that on August 28, 2025, the company first implemented a share repurchase of 211,200 shares through a dedicated stock repurchase account via centralized bidding, accounting for 0.13% of the company's current total share capital. The highest transaction price for the repurchased shares was RMB 29.34 per share, the lowest transaction price was RMB 27.3 per share, and the total amount paid was RMB 5.9071 million. This repurchase complies with the company's established repurchase plan and relevant laws and regulations

Tellgen: First repurchase of 0.13% of the company's shares

Tellgen announced that its operating revenue in the first half of 2025 was 159 million yuan, a year-on-year decrease of 26.25%. The net profit was 2.7593 million yuan, a year-on-year decrease of 58.41%

Tellgen: Net profit of 2.7593 million yuan in the first half of 2025, a year-on-year decrease of 58.41%

301421

688114

300244

000710

The gene sequencing sector saw a short-term surge, with Berry Genomics hitting the limit up, while MGI, Dian Diagnostics, Antu Biology, Wavelength OE, Tellgen, and others all rose

Wavelength OE

Dian Diagnostics

Berry Genomics

The gene sequencing sector surged in the short term, and Berry Genomics hit the limit up

Tellgen's wholly-owned subsidiary Jiangxi Tellgen recently obtained two medical device registration certificates issued by the Jiangxi Provincial Drug Administration. These two products are the anti-histidyl tRNA synthetase antibody IgG test kit and the anti-transcription intermediary factor 1-γ antibody IgG test kit, mainly used for the auxiliary diagnosis of polymyositis/dermatomyositis

Tellgen's subsidiary Jiangxi Tellgen has obtained two medical device registration certificates

Tellgen plans to acquire 72.8630% of Wuhan Kanglu Bio's shares for a transaction amount of 291 million yuan. Upon completion, Kanglu Bio will become its subsidiary. If conditions are met, it will further acquire 9.1370% of the shares in 2026 and 2027, ultimately reaching a shareholding of 82.00%. Kanglu Bio focuses on molecular diagnostics fields such as fluorescence in situ hybridization (FISH) and PCR, and this transaction is expected to bring synergies, enhancing the company's competitiveness and revenue growth

Tellgen plans to acquire controlling stake in Kanglu Bio to pursue synergies

002370

002022

300482

688317

002030

The monkeypox concept has seen a surge, with KHB hitting the limit up, and DAJY, Yatai pharm, Lanwei Medical, WONDFO BIOTECH, Tellgen, and LIFERIVER also rising

Yatai pharm

WONDFO BIOTECH

LIFERIVER

DAJY

Monkeypox concept stocks surged, KHB hit the limit up

Tellgen announced that the company recently received the "Medical Device Change Registration Document" issued by the National Medical Products Administration, completing the changes related to the original registration certificate for the "Human Papillomavirus Nucleic Acid Detection and Typing Kit for 16/18/52/58/33." At the same time, its wholly-owned subsidiary Jiangxi Tellgen obtained 5 medical device registration certificates issued by the Jiangxi Provincial Medical Products Administration

Tellgen: Obtained the change registration and registration certificate for medical devices

Tellgen's wholly-owned subsidiary Jiangxi Tellgen Life Science Technology Co., Ltd. recently obtained two medical device registration certificates issued by the Jiangxi Provincial Drug Administration. These products include the Fibrin (ogen) Degradation Products Detection Kit and the Plasmin-α2 Plasmin Inhibitor Complex Detection Kit. The acquisition of these registration certificates will enrich the company's chemiluminescence product line, meet the clinical needs for thrombosis testing, enhance the company's competitiveness in the in vitro diagnostic field, and promote market expansion

Tellgen's subsidiary obtained 2 medical device registration certificates

Tellgen(300642.SZ)